Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Atrium Therapeutics, Inc. (RNA) had Return on Equity of 43.39% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$18.75M |
|
$-684.63M |
|
-- |
|
$18.75M |
|
$205.54M |
|
$-186.78M |
|
$61.31M |
|
$-684.63M |
|
$-684.63M |
|
$-684.63M |
|
$-684.63M |
|
$-684.63M |
|
$-684.63M |
|
$-186.78M |
|
$-186.78M |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$1.80B |
|
$23.33M |
|
$23.33M |
|
$1.96B |
|
$195.45M |
|
-- |
|
-- |
|
$269.45M |
|
$-1.58B |
|
$1.69B |
|
$1.69B |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-995.92% |
|
-995.92% |
|
-995.92% |
|
-3650.39% |
|
-3650.39% |
|
-- |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
43.39% |
-40.54% |
|
-34.96% |
|
-40.54% |
|
-- |
|
-- |
|
-- |
|